← Back to Clinical Trials
Recruiting NCT07521085

NCT07521085 Combined Effects Of Stability Oriented Breathing Exercises and Kegel's Exercises in Postpartum Women

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07521085
Status Recruiting
Phase
Sponsor Riphah International University
Condition Postpartum Complication
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-08-31
Primary Completion 2026-09

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 40 Years
Study Type INTERVENTIONAL
Interventions
Stability Oriented Breathing Trainingkegels exercises

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-08-31 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The postpartum period often presents challenges such as increased inter-recti distance (diastasis recti), lumbopelvic pain, and reduced core strength. This study is designed as a randomized controlled trial to evaluate the combined effects of stability-oriented breathing exercises and Kegel exercises on inter-recti distance (IRD), lumbopelvic pain, and muscle strength in postpartum women. A total sample size of 66 participants per group was determined with a 10% dropout rate accounted for. The study will use a non-probability convenience sampling technique. It will be conducted at the University of Lahore Teaching Hospital and Sehat Medical complex. Inclusion criteria include women aged 18-40 years, with a history of cesarean sections, an IRD between 3-5 cm. Outcome measures include IRD , pelvic floor muscle strength, lumbopelvic pain (measured using a 10 cm numeric pain scale). Participants will be randomly assigned to either Group A (Kegel-only) or Group B (Kegel + breathing exercises). Both groups will train three times weekly for eight weeks. All data analysis will be performed using SPSS version 27.

Eligibility Criteria

Inclusion Criteria: * • Age between 18-40 years * Postpartum duration of 42-49 days * Inter-recti distance (IRD) between 3-5 cm * Numeric pain scale score ≤ 6 for pain * No prior physiotherapy or exercise guidance received Exclusion Criteria: * • Pain during the training period * Patients with any heart or respiratory disease including excessive coughing and sneezing * Patients with any kind of pelvic or abdominal surgery * Significant organ dysfunction or psychiatric illness * Diagnosis of malignant tumors

Contact & Investigator

Central Contact

imran amjad, phd

✉ imran.amjad@riphah.edu.pk

📞 03324390125

Principal Investigator

Masooma Saleem, MSPT WH

PRINCIPAL INVESTIGATOR

Riphah International University

Frequently Asked Questions

Who can join the NCT07521085 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Postpartum Complication. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07521085 currently recruiting?

Yes, NCT07521085 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.

Where is the NCT07521085 trial being conducted?

This trial is being conducted at Lahore, Pakistan, Lahore, Pakistan.

Who is sponsoring the NCT07521085 clinical trial?

NCT07521085 is sponsored by Riphah International University. The principal investigator is Masooma Saleem, MSPT WH at Riphah International University. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology